In present study, the attempts have been made to formulate sustained release tablets of lornoxicam by direct compression method. Based on viscosity grades different proportions of hydrophilic polymers (HPMC K4M, HPMC K15M, HPMC K100M) are used for preparation of lornoxicam sustained release matrix tablet. The drug excipient mixtures were subjected to preformulation studies comprising of micromeritic properties. The tablets were subjected to various studies like as physicochemical studies, in vitro drug release, kinetic studies, etc. FTIR studies shown there was no interaction between drug and polymers. The physicochemical properties of tablets were found within the limits. Lornoxicam is a first generation analgesic, inflammatory and antipyr...
To select the suitable concentration level of controlled release polymer for the formulation of pred...
The study was carried to formulate and evaluate dispersible tablet dosage form containing Lornoxicam...
Objective: To develop in-situ gel formulations of Lornoxicam for sustained release to reduce the dos...
In present study, the attempts have been made to formulate sustained release tablets of lornoxicam b...
The aim of the present work was to develop controlled release matrix tablets of Lornoxicam using pol...
The main aim of the study formulation and evaluation of the lornoxicam sustained release tablets by ...
Purpose: To formulate double-layer tablets of lornoxicam (LRX) prepared by direct compression method...
In the present study efforts have been made to prepare sustained release matrix tablets of Lornoxica...
This bi-layer matrix tablets were formulated to show quick onset of action as well as prolonged effe...
The present investigation is concerned with development and evaluation of Sustained release matrix t...
Aim of the present study was to develop site-specific drug delivery system of lornoxicam for the tre...
Lornoxicam is a NSAID having oxicam class mainly prescribed in the treatment of osteoarthritis and r...
Implementation of time release technology in formulation development and evaluation of sustained rel...
In present investigation an attempt has been made to design and develop Ibuprofen sustained release ...
Various types of controlled release dosage forms such as wax matrix hydrophilic polymer matrix, osmo...
To select the suitable concentration level of controlled release polymer for the formulation of pred...
The study was carried to formulate and evaluate dispersible tablet dosage form containing Lornoxicam...
Objective: To develop in-situ gel formulations of Lornoxicam for sustained release to reduce the dos...
In present study, the attempts have been made to formulate sustained release tablets of lornoxicam b...
The aim of the present work was to develop controlled release matrix tablets of Lornoxicam using pol...
The main aim of the study formulation and evaluation of the lornoxicam sustained release tablets by ...
Purpose: To formulate double-layer tablets of lornoxicam (LRX) prepared by direct compression method...
In the present study efforts have been made to prepare sustained release matrix tablets of Lornoxica...
This bi-layer matrix tablets were formulated to show quick onset of action as well as prolonged effe...
The present investigation is concerned with development and evaluation of Sustained release matrix t...
Aim of the present study was to develop site-specific drug delivery system of lornoxicam for the tre...
Lornoxicam is a NSAID having oxicam class mainly prescribed in the treatment of osteoarthritis and r...
Implementation of time release technology in formulation development and evaluation of sustained rel...
In present investigation an attempt has been made to design and develop Ibuprofen sustained release ...
Various types of controlled release dosage forms such as wax matrix hydrophilic polymer matrix, osmo...
To select the suitable concentration level of controlled release polymer for the formulation of pred...
The study was carried to formulate and evaluate dispersible tablet dosage form containing Lornoxicam...
Objective: To develop in-situ gel formulations of Lornoxicam for sustained release to reduce the dos...